The complex regulation of TGF-β in cardiovascular disease

Abstract: Transforming growth factor β (TGF-β1) is a pleiotropic cytokine with many and complex effects in cell and tissue physiology. This is made possible by a very complex and interwoven signaling system, whose regulation continues to be the focus of a growing line of research. This complex regulation translates to a key role in cardiovascular physiology, hemostasis, and the blood–vessel interface. In accordance with this, the TGF-β1 pathway appears to be deregulated in related disorders, such as atherosclerotic vascular disease and myeloproliferative syndromes. It is expected that the growing amount of experimental and clinical research will yield medical advances in the applications of knowledge of the TGF-β1 pathway to diagnosis and therapeutics.

Keywords: transforming growth factor beta, pathway, Smads, non-Smads, atherosclerosis, myeloproliferative syndromes

Introduction

Transforming growth factor β (TGF-β1) is a pleiotropic cytokine, which has been demonstrated to regulate a wide array of biological processes. It plays a major role in the regulation of vascular function and hemostasis. Therefore, it can be considered as a putative therapeutic target in disorders of the blood–vessel interface, such as atherosclerosis and myeloproliferative syndromes. The present narrative review highlights the most important advances in the knowledge of TGF-β regulation in cardiovascular disease. This review has been prepared after a comprehensive search through MEDLINE. Search terms were “TGF beta”, “cardiovascular”, “atherosclerosis”, “myeloproliferative syndromes”, “pathway”, and “regulation”. A broader coverage of research strategy can be found in Gasparyan et al.1

Regulation of TGF-β1 physiology

The canonical TGF-β1 pathway

The regulation of TGF-β1 is shown in Figure 1. Briefly, active TGF-β1 is released from its latency-associated peptide by activating proteases. Then, it binds to the TGF-β-RII, which acts as a Ser/Thr kinase.2 This Ser/Thr kinase activity phosphorylates TGF-β-RI which may be present in several isoforms termed activin-like kinases (ALKs).3 In general, TGF-β1 stimulates ALK-5 and phosphorylates second messenger proteins termed Smads.4 Smad2 or Smad3 form a heterodimer with Smad4, and internalize into the nucleus to decrease the proliferation/apoptosis ratio,5 increase differentiation,6 and inhibit the expression of inflammatory molecules.7
New insights in TGF-β1 regulation

In recent years, a growing body of experimental medicine suggests an important role of several factors which may act (in a real-time manner) as rheostats for the fine tuning of the TGF-β1 pathway, and thus adapt cell response of TGF-β1 to a given cellular circumstance.

The first important factor is receptor endocytosis. Recent reports indicate that receptor endocytosis is a key event in proper signaling and receptor recycling. Moreover, it has been clarified that clathrin-coated pits-mediated endocytosis enhances TGF-β function, and that early endosomes behave as signaling organelles to promote TGF-β signaling. Conversely, however, the lipid rafts-caveolae endocytic system inhibits TGF-β signaling. Interestingly, it has been described that, given that caveolae localize in cholesterol-rich membrane domains, cholesterol itself inhibits TGF-β signaling in vitro, and this might mediate, at least in part, atherogenic effects of cholesterol in vivo. In fact, caveolin, a protein that is a key component of caveolae, physically interacts with TGF-β-R-I to block Smad signaling.

The second key event is micro-RNA (miRNA) regulation. This is achieved by noncoding RNA fragments which are able to silence gene expression. In particular, the miRNA 200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) cooperate with TGF-β signaling to regulate epithelial-to-mesenchymal transition. Interestingly, other miRNAs are able to inhibit the antitumor effects of TGF-β and thus are accumulated in human tumors, as seen with the miRNA 25 cluster (miRNA 106b, miRNA 93, and miRNA 25) in gastric cancer, neuroblastoma, and multiple myeloma; and the miRNA 17-92 cluster (miRNA 17, miRNA 18a, miRNA 19a, miRNA 20a, miRNA 19b-1, miRNA 92a) in diffuse large B cell lymphoma and small-cell lung cancer. MiRNAs miRNA 106b-25 and miR-92 regulate TGF-β-mediated antiproliferative and apoptotic effects. In particular, miR-106b and miR-93 inhibit TGF-β-mediated cell cycle arrest, whereas miR-25 inhibits TGF-β-mediated apoptosis. Of note, this crosstalk between the TGF-β pathway and miRNA seems to be a bidirectional process. Thus, miRNA not only affects the TGF-β pathway, but also, miR-21 is directly upregulated by TGF-β signaling in vitro, and this might mediate, at least in part, atherogenic effects of cholesterol in vivo. In fact, caveolin, a protein that is a key component of caveolae, physically interacts with TGF-β-R-I to block Smad signaling.

In endothelial cells, TGF-β1 can stimulate ALK-4/5/7 and Smad2/3, or stimulate ALK-1 and Smad1/5/8 and increase cell proliferation. Smad6 and 7 are inhibitory Smads, since they bind Smad4 and inhibit its internalization into the nucleus. Endoglin is an accessory to the TGF-β receptor that seems to modulate receptor binding and ALK stimulation. It is mutated in hereditary hemorrhagic telangiectasia type 1, whereas ALK-1 is mutated in hereditary hemorrhagic telangiectasia type 2.

In addition to this classical Smad-dependent pathway, other crosstalks have been described among TGF-β1 and several signaling pathways, including mitogen-activated protein (MAP) kinases and small GTPases, such as RhoA.

Non-Smad pathways seem to be especially important to regulate the TGF-β-mediated fibrotic effect. In particular, focal adhesion kinase has been shown to regulate TGF-β-mediated fibrosis. This is mediated by a TGF-β-mediated recruitment of the p85 subunit of PI3K to focal adhesion kinase to regulate signal transduction, which is independent of tyrosine kinase activation. Among MAP kinases, JNK plays a necessary role in mediating TGF-β-mediated epithelial-to-mesenchymal transition in rat peritoneal fibroblasts, in cooperation with Smad3. In addition, the ERK MAP kinase regulates epithelial-to-mesenchymal transition in mesothelial cells by involving nuclear factor-κB (NFκB). Conversely, p38 MAP kinase seems to inhibit this effect in the same cell model. This antifibrotic effect of TGF-β is also mediated by peroxisome proliferator-activated receptor-γ by preventing p300 recruitment, subsequent histone H4 hyperacetylation, and eventual collagen synthesis.
A third emerging mechanism to control the complex regulation of TGF-β1 signaling is the cytoskeleton. Smads are tightly anchored to the cytoskeleton and constantly shuttle the cytoplasm and the nucleus in basal cell conditions. In fact, all Smads are associated to cell microtubules and their trafficking is controlled, at least in part, by microtubule-related proteins, such as kinesin for going to cell membrane receptors, and dynein when they direct to the nucleus. In cell culture models, nuclear accumulation of Smads has been considered to be a direct marker of TGF-β1 signaling, and this could be mediated by nuclear phosphatases, which dephosphorylate the C-terminal di-serine motifs Smads.

Yet again, this link between TGF-β and cytoskeleton acts in a bidirectional manner, given that TGF-β regulates actin polymerization by the non-Smad-signaling pathways RhoA and p38, and by affecting epithelial-to-mesenchymal transition.

In recent years, several mathematical models have been developed that will predict the cell response of TGF-β1 in a given circumstance in silico, and thus help to design target-designed novel molecules, in order to modulate the important roles exerted by TGF-β1 signaling in health and disease. These models are based on a network of molecular components. In order to describe how a given parameter changes with time, systems of ordinary differential equations were incorporated to build a kinetic model, since these could express molecular changes (concentrations and biochemical modifications) over time, and relate these data to empirical ones.

**TGF-β1 in cardiovascular disease**

**TGF-β1 in vascular and hemostasis physiology**

In general, TGF-β1 is considered as an anti-inflammatory cytokine in the vessel wall. In normal vessels, TGF-β1 inhibits endothelial and vascular smooth muscle cell proliferation. It also increases apoptosis to avoid excessive cellular accumulation, and stimulates vascular cell differentiation, with a parallel decrease of the expression of inflammatory molecules. In the blood–vessel interface, TGF-β1 decreases expression of cell adhesion molecules in vascular cells. In addition, in leukocytes, it decreases the activation of integrins and stimulates the function of endothelial progenitor cells, which may help to restore the denuded vessel wall. In hemostasis, TGF-β1 seems to behave as an antifibrinolytic factor and stimulates platelet-induced vascular repair. TGF-β1 is a normal component of platelet alpha granules. In fact, the vast majority of serum TGF-β1 comes from platelet degranulation.

**TGF-β1 in atherosclerosis**

In atherosclerosis, TGF-β1 is considered to be an antiatherogenic factor, especially in the early stages of the disease, according to what has been termed the protective cytokine hypothesis. Thus, TGF-β1 inhibits excessive vascular smooth muscle cell accumulation in the neointima, and avoids plaque rupture by means of its stimulation of extracellular matrix synthesis and tissue repair. In addition, it controls local inflammation by stimulating Th3 function and regulatory T cells (CD3+/CD25+ cells). Therefore, it avoids the excessive immune attack (from both innate and acquired immunity mechanisms) that characterizes atherosclerotic vascular disease. In the clinical arena, decreased serum levels of TGF-β1 have been correlated to clinical atherosclerosis. However, this parameter has remained an elusive atherosclerosis marker, given that these levels may vary according to the time course of the disease and age. The majority of serum TGF-β1 levels originate from platelets and thus are markers of platelet activation in atherosclerosis and rheumatoid arthritis. TGF-β levels can be calculated as an active or total (active and acid-activatable) form. In systemic lupus erythematosus patients, a lower serum activation index has been associated with increased lymphocyte apoptosis, irreversible organ damage, disease duration, low-density lipoprotein, and increased carotid intima-media thickness. Endoglin is an accessory TGF-β receptor and soluble endoglin may interfere with TGF-β interaction with membrane-bound receptors and thus decrease TGF-β signaling. Increased levels of soluble endoglin have been related to atherosclerosis, as well as preeclampsia.

However, in late stages of the disease, TGF-β1 seems to behave as a proatherogenic factor by increasing excessive extracellular matrix, promotion of in-stent restenosis, and induction of pathologic vascular remodeling. In fact, it has been demonstrated that end-organ damage in hypertension has been related to increased levels of TGF-β1 in serum and urine. Moreover, in atherosclerotic vascular disease, it has been demonstrated that cells become insensitive to TGF-β1 signaling by means of decreased TGF-β1 activation, decreased receptor and Smad downregulation, altered endocytosis and intracellular trafficking pattern, or alteration of any of the other multiple cellular pathways that crosstalk with the TGF-β1 signaling pathway. Interestingly, many of these factors may be altered at the genetic level by means of congenital atherosclerotic-related polymorphisms and genetic determinants of aortic aneurysms. Moreover, even acquired mutations have been postulated to modulate these facts.
TGF-β1 in myeloproliferative syndromes

Philadelphia-negative myeloproliferative syndromes (polycythemia vera, essential thrombocytosis, essential myelofibrosis) are clonal hematological neoplasms in which an increased risk of arterial thrombosis occurs. A growing body of clinical and experimental evidence suggests that these variable phenotypes can follow a graded natural history, from initial essential thrombocytosis to subsequent polycythemia vera, and eventual spent-phase secondary myelofibrosis. These three disorders are associated with increased risk of arterial thrombosis, and in polycythemia vera, this risk is 20% at 10 years.

In essential thrombocytosis, the abnormal clone seems to lose sensitivity to the proliferation-control effects of TGF-β1. In polycythemia vera, the abnormal clone equally loses response to the cytokine.

However, essential or secondary myelofibrosis is the chronic myeloproliferative syndrome which is associated with the shortest survival rate. The risk of thrombosis is similar to that found in essential thrombocytemia (1%-3% per patient per year). This is the variant of myeloproliferative syndrome which has the strongest link to dysregulation of the TGF-β1 pathway. In fact, TGF-β increases myelofibrosis in murine models. In cell culture models, TGF-β secretion seems to be regulated by NFκB. In myeloproliferative syndromes, there seems to be a progressive grading in TGF-β1 in the prefibrotic state, although established myelofibrosis has lower TGF-β1 levels. Higher TGF-β levels seem to be correlated with increased allelic charge of JAK2, and decreased EPC levels.

Therapy of myelofibrosis is a clinical challenge and supportive care has been the only treatment to date. Current JAK-2 inhibitors have shown only a limited benefit in regard to spleen size. Advances in the knowledge of TGF-β signaling in myeloproliferative syndromes may guide the choice of synergistic novel therapies such as small-molecule TGF-β pathway blockers including, SB-431542/ALK-4 inhibitor of the ALK-4 kinase activity, heat-shock protein inhibitors, NFκB inhibitors, or epigenetic drugs.

Thus, progressive TGF-β dysfunction can be considered as a shared pathogenic event in atherosclerosis and Philadelphia-negative myeloproliferative syndromes, and a putative diagnostic and therapeutic tool.

Conclusion

TGF-β1 is a key factor in diseases affected by cardiovascular disorders, such as atherosclerosis and myeloproliferative syndromes. The current knowledge of the complex TGF-β1 regulation of physiological and pathological processes may help to design novel diagnostic techniques and target-designed innovative therapies.

Authors’ contributions

SR conceived the idea of the manuscript and wrote the first schematic draft. SR and TT designed the search strategy. SR, JN-D, MR, UM, and TT performed the review of the literature. All authors collaborated in the definitive version, and approved the final draft of the manuscript.

Acknowledgment/disclosure

Our lab received support by FISS (Health Research Fund, PI080920) and Red Temática de Investigación Cardiovascular RECAVA (RD06/0014/1007), both from the Instituto de Salud Carlos III, Spanish Ministry of Health (ISCIII). The authors report no conflicts of interest in this work.

References

1. Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD. Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int. 2011;31(11):1409–1417.
2. Redondo S, Santos-Gallego CG, Tejerina T. TGF-beta1: a novel target for cardiovascular pharmacology. Cytokine Growth Factor Rev. 2007; 18(3–4):279–286.
3. Lebrin F, Goumans MJ, Jonker L, et al. Smad7-deficient mice show synergistic novel therapies such as small-molecule TGF-beta binding protein (β-B) inhibitors, or epigenetic drugs.
4. Loureiro J, Schilte M, Aguilera A, et al. BMP-7 blocks mesenchymal conversion of mesothelial cells and prevents peritoneal damage induced by dialysis fluid exposure. Nephrol Dial Transplant. 2010;25(4):1098–1108.
5. Redondo S, Ruiz E, Santos-Gallego CG, Padilla E, Tejerina T. Pioglitazone induces vascular smooth muscle cell apoptosis through a peroxisome proliferator-activated receptor-gamma, transforming growth factor-beta1, and a Smad2-dependent mechanism. Diabetes. 2005;54(3):811–817.
6. Tang Y, Yang X, Friesel RE, Vary CP, Liaw L. Mechanisms of TGF-β1-induced differentiation in human vascular smooth muscle cells. J Vasc Res. 2011;48(6):485–494.
7. Azuma M, Motegi K, Aota K, Yamashita T, Yoshida H, Sato M. TGF-beta1 inhibits NF-kappaB activity through induction of IkappaB-alpha expression in human salivary gland cells: a possible mechanism of growth suppression by TGF-beta1. Exp Cell Res. 1999;250(1):213–222.
8. Goumans MJ, Valdimarsdottir G, Itoh S, et al. Actin-dependent receptor-like kinase (ALK1) is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol Cell. 2003;12(4):817–828.
9. Tojo M, Takebe A, Takahashi S, et al. Smad7-deficient mice show growth retardation with reduced viability. J Biochem. 2012;151(6):621–631.
10. Lebrin F, Deckers M, Bertolino P, Ten Dijke P. TGF-beta receptor function in the endothelium. Cardiovasc Res. 2005;65(3):599–608.
11. McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary hemorrhagic telangiectasia type 1. Nat Genet. 1994;8(4):345–351.
Berg JN, Gallione CJ, Stenzel TT, et al. The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2. *Am J Hum Genet.* 1997;61(1):60–67.

Moustakas A, Heldin CH. Non-Smad TGF-beta signals. *J Cell Sci.* 2005;118(Pt 16):3573–3584.

Yang F, Chung AC, Huang XR, Lan HY. Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent Smad pathways: the role of Smad3. *Hypertension.* 2009;54(4):877–884.

Tsapara A, Luthert P, Greenwood J, Hill CS, Matter K, Balda MS. The RhoA activator GEF-H1/Flc is a transforming growth factor-beta target gene and effector that regulates alpha-smooth muscle actin expression and cell migration. *Mol Biol Cell.* 2010;21(6):860–870.

Hong M, Wilkes MC, Penheteri SG, Gupta SK, Edens M, Leof EB. Non-Smad transforming growth factor-beta signaling regulated by focal adhesion kinase binding the p85 subunit of phosphatidylinositol 3-kinase. *J Biol Chem.* 2011;286(20):17841–17850.

Liu Q, Zhang Y, Mao H, et al. A cross-talk between the Smad and JNK signaling in the TGF-beta/Smad pathway. Cell Death Biol. 2012;19(1):58–70.

Hayes S, Chawla A, Corvera S. TGF beta receptor internalization into vascular smooth muscle cells. *Vasc Health Risk Manage* 2012;8:306–312.

Kumarswamy R, Volkmann I, Jazbutyte V, Dangwal S, Park DH, Thum T. Essential and overlapping functions of the miR-17 through 92 family. *Cell Rep.* 2015;12(1):1–12.

Petrocca F, Visone R, Onelli MR, et al. E2F1-regulated microRNAs miR-205 regulate epithelial to mesenchymal transition by targeting Caveolin1. *Cell Cycle.* 2012;11(8):1751–1759.

Saradha T, Jayalakshmi J, Sheela B, et al. TGF-beta1 signaling in the TGF-beta receptor-gamma abrogates Smad-dependent collagen stimulation by transforming growth factor-beta-JNK signaling pathway. *Am J Transplant.* 2010;10(1):357–368.

Chen YG. Endocytic regulation of TGF-beta signaling. *Cell Res.* 2009;19(1):58–70.

Hayes S, Chawla A, Corvera S. TGF-beta receptor internalization into EEA1-enriched early endosomes: role in signaling to Smad2. *J Biol Chem.* 2002;277(7):6239–6249.

Razani B, Zhang XL, Bitzer M, von Gersdorff G, Böttinger EP, Lisanti MP. Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta type I receptor. *Caveolin-1.* 2003;10(5):593–601.

Jaffe M, Sesti C, Washington IM, et al. Transforming growth factor-beta-induced ET-1 expression in endothelial cells: a role for migration and proliferation. *J Cell Sci.* 2007;120(Pt 7):1256–1266.

Ruiz E, Redondo S, Gordillo-Moscoso A, Tejerina T. Pioglitazone inhibits cellular TGF-beta responsiveness: implications in atherogenesis. *Arterioscler Thromb Vasc Biol.* 2009;29(9):1912–1918.

Atsuta H, Nakagawa Y, Kishida T, et al. The effect of pioglitazone on isolated human endothelial progenitor cells: a role for migration and proliferation. *Arterioscler Thromb Vasc Biol.* 2009;29(9):1912–1918.

Anitua E, Aguirre JJ, Algorta J, et al. Effectiveness of autologous preparation of dermal tissue rich in growth factors for the treatment of chronic cutaneous ulcers. *J Biomed Mater Res B Appl Biomater.* 2008;84(2):415–421.

Batut J, Howell M, Hill CS. Kinesin-mediated transport of Smad2 is required for signaling in response to TGFbeta ligands. *Dev Cell.* 2007;12(2):261–274.

Jin Q, Ding W, Mulder KM. Requirement for the dynacin light chain km23-21 in a Smad2-dependent transforming growth factor-beta signaling pathway. *J Biol Chem.* 2007;282(26):19122–19132.

Kurisaki A, Kose S, Yokeda Y, Heldin CH, Moustakas A. Transforming growth factor-beta induces nuclear import of Smad3 in an importin-beta I and Ran-dependent manner. *Mol Biol Cell.* 2001;12(4):1079–1091.

Chen HB, Rud JG, Lin k, Xu H. Nuclear targeting of transforming growth factor-beta-activated Smad complexes. *J Biol Chem.* 2005;280(22):21329–21336.

Knockaert M, Sapkota G, Alarcon C, Massaquier J, Brivanlou AH. Unique players in the BMP pathway: small C-terminal domain phosphatases dephosphorylate Smad1 to attenuate BMP signaling. *Proc Natl Acad Sci USA.* 2006;103(32):11940–11945.

Vardoulis L, Moustakas A, Stournaras C. LIM kinase and cofillin phosphomutation mediate actin cytoskeleton reorganization induced by transforming growth factor-beta. *J Biol Chem.* 2005;280(12):11448–11457.

Clarke DC, Liu X. Decoding the quantitative nature of TGF-beta/MAPK signaling. *Trends Cell Biol.* 2008;18(9):430–442.

Lebastchi AH, Khan SF, Qin L, et al. Transforming growth factor beta expression by human vascular cells inhibits interferon gamma production and arterial media injury by alloreactive memory T cells. *Am J Transplant.* 2011;11(11):2332–2341.

Castañeres C, Redondo-Horcajo M, Magán-Marchal N, ten Dijke P, Lamas S, Rodriguez-Pascual F. Signaling by ALK5 mediates TGF-beta-induced ET-1 expression in endothelial cells: a role for migration and proliferation. *J Cell Sci.* 2007;120(Pt 7):1256–1266.

Redondo S, Santos-Gallego CG, Gandano P, et al. Acetylsalicylic acid inhibits cell proliferation by involving transforming growth factor-beta. *Circulation.* 2003;107(4):626–629.

Ruiz E, Redondo S, Gordillo-Moscoso A, Tejerina T. PIGF stimulates ET-1 expression in endothelial cells and increases leukocyte rolling. Inhibition of VEGF or TGF-b signaling activates endothelium and increases leukocyte rolling. *Arterioscler Thromb Vasc Biol.* 2012;32(1):e1–e11.

Feinberg MW, Watanabe M, Lebedeva MA, et al. Transforming growth factor-beta inhibition of vascular smooth muscle cell activation is mediated via Smad3. *J Biol Chem.* 2004;279(16):16388–16393.

Walshe TE, Dole VS, Maharaj AS, Pattern IS, Wagner DD, D’Amore PA. Inhibition of VEGF or TGF-beta signaling activates endothelium and increases leukocyte rolling. *Arterioscler Thromb Vasc Biol.* 2009;29(8):1185–1192.

Basoni C, Nobles M, Grinshaw A, et al. Inhibitory control of TGF-beta1 on the activation of Rap1, CD11b, and transendothelial migration of leukocytes. *FASEB J.* 2005;19(7):822–824.

Redondo S, Hristov M, Giümbel D, Tejerina T, Weber C. Biaphasic effect of pigf on isolated human endothelial progenitor cells: involvement of peroxisome proliferator-activated receptor-gamma and transforming growth factor-beta1. *Thromb Haemost.* 2007;97(6):979–987.

Vayali PK, Olman M, Murphy-Ullrich JE, Postlethwait EM, Liu RM. Glutathione restores collagen degradation in TGF-beta-treated fibroblasts by blocking plasminogen activator inhibitor-1 expression and activating plasminogen. *Am J Physiol Lung Cell Mol Physiol.* 2005;289(6):L937–L945.

Anitua E, Aguirre JJ, Algorta J, et al. Effectiveness of autologous preparation in growth factors for the treatment of chronic cutaneous ulcers. *J Biomed Mater Res B Appl Biomater.* 2008;84(2):415–421.
50. Meyer A, Wang W, Qu J, et al. Platelet TGF-β1 contributions to plasma TGF-β1, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload. Blood. 2012;119(4):1064–1074.
51. Grainger DJ, Mosedale DE, Metcalfe JC, Weissberg PL, Kemp PR. Active and acid-activatable TGF-beta in human sera, platelets and plasma. Clin Chim Acta. 1995;235(1):11–31.
52. Grainger DJ. Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol. 2004;24(3):399–404.
53. Lutgens E, Gibjels M, Snook M, et al. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol. 2002;22(6):975–982.
54. Dai J, Michineau S, Franck G, et al. Long term stabilization of expanding aortic aneurysms by a short course of cyclosporine A through transforming growth factor-beta induction. PLoS One. 2011;6(12):e28903.
55. Ji QW, Guo M, Zheng JS, et al. Downregulation of T helper cell type 3 in patients with acute coronary syndrome. Arch Med Res. 2009;40(4):285–293.
56. Koenen RR, Weber C. Chemokines: established and novel targets in atherosclerosis. EMBO Mol Med. 2011;3(12):713–725.
57. Okamoto Y, Gotoh Y, Uemura O, Tanaka S, Ando T, Nishida M. Age-dependent decrease in serum transforming growth factor (TGF)-beta 1 in healthy Japanese individuals; population study of serum TGF-beta 1 level in Japanese. DisMarkers. 2005;21(2):71–74.
58. Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Douglas KM, Kitas GD. Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int. 2011;31(2):153–160.
59. Jackson M, Ahmad Y, Bruce IN, Coupes B, Brenchley PE. Activation of transforming growth factor-beta and early atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2006;58(3):R81.
60. López-Novoa JM, Bernabeu C. The physiological role of endoglin in the cardiovascular system. Am J Physiol Heart Circ Physiol. 2010;299(4):H959–H974.
61. Blázquez-Medela AM, García-Ortiz L, Gómez-Marcos MA, et al. Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. BMC Med. 2010;8:86.
62. López-Novoa JM. Soluble endoglin is an accurate predictor and a pathogenic molecule in pre-eclampsia. Nephrol Dial Transplant. 2007;22(3):712–714.
63. Dees C, Akhmetshina A, Zerr P, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med. 2010;208(5):961–972.
64. Pallero MA, Talbert Roden M, Chen YF, et al. Stainless steel ions induce increased thrombospondin-1-dependent TGF-beta activation by vascular smooth muscle cells: implications for in-stent restenosis. J Vasc Res. 2010;47(4):309–322.
65. Kiec-Wilk B, Stolarz-Skrzypek K, Sliva A, Zdienicka A, Kawecka-Jaszcz K. Peripheral blood concentrations of TGFβ1, IGF-1 and bFGF and remodeling of the left ventricle and blood vessels in hypertensive patients. Kardiol Pol. 2010;68(9):996–1002.
66. Lavadiès C, Varo N, Díez J. Transforming growth factor beta in hypertensives with cardioareal damage. Hypertension. 2000;36(4):517–522.
67. Sakamoto Y, Miyazaki T, Kamagawa H, Wang GP, Horiiuchi S. Specific interaction of oxidized low-density lipoprotein with thrombospondin-1 inhibits transforming growth factor-beta from its activation. Atherosclerosis. 2005;183(1):85–93.
68. McCaffrey TA, Du B, Fu C, et al. The expression of TGF-beta receptors in human atherosclerosis: evidence for acquired resistance to apoptosis due to receptor imbalance. J Mol Cell Cardiol. 1999;31(9):1627–1642.
69. Kalinina N, Agrotis A, Antropova Y, et al. Smad expression in human atherosclerotic lesions: evidence for impaired TGF-beta/Smad signaling in smooth muscle cells of fibrofatty lesions. Arterioscler Thromb Vasc Biol. 2004;24(8):1391–1396.
70. Rao M, Guo D, Jaber BL, Tighiouart H, Pereira BJ, Balakrishnan VS, for HEMO Study Group. Transforming growth factor-beta 1 gene polymorphisms and cardiovascular disease in hemodialysis patients. Kidney Int. 2004;66(1):419–427.
71. Sie MP, Uitterlinden AG, Bos MJ, et al. TGF-beta 1 polymorphisms and risk of myocardial infarction and stroke: the Rotterdam Study. Stroke. 2006;37(11):2667–2671.
72. Peng Z, Zhan L, Chen S, Xu E. Association of transforming growth factor-beta 1 gene C-509T and T869C polymorphisms with atherosclerotic cerebral infarction in the Chinese: a case-control study. Lipids Health Dis. 2011;10:100.
73. Biros E, Norman PE, Jones GT, et al. Meta-analysis of the association between single nucleotide polymorphisms in TGF-β receptor genes and abdominal aortic aneurysm. Atherosclerosis. 2011;219(1):218–223.
74. Clark KJ, Cary NR, Grace AA, Metcalfe JC. Microsatellite mutation of type II transforming growth factor-beta receptor is rare in atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001;21(4):555–559.
75. Alvarez-Larrán A, Pereira A, Cervantes F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood. 2012;119(6):1363–1369.
76. Kuroda H, Matsunaga T, Terui T, et al. Decrease of Smad4 gene expression in patients with essential thrombocythaemia may cause an escape from suppression of megakaryopoiesis by transforming growth factor-beta1. Br J Haematol. 2004;124(2):211–220.
77. Li J, Bench AJ, Hunte BJ, Green AR. Mutation and methylation analysis of the transforming growth factor beta receptor II gene in polycythemia vera. Br J Haematol. 2001;115(4):872–880.
78. Vannucci AM. Management of myelofibrosis. Hematology Am Soc Hematol Educ Program. 2011;2012:222–230.
79. Ponce CC, de Lourdies F, Chauffaille M, Ibara SS, Silva MR. The relationship of the active and latent forms of TGF-β1 with marrow fibrosis in essential thrombocytopenia and primary myelofibrosis. Med Oncol. December 27, 2011. [Epub ahead of print.]
80. Gasztiné T, Vigant F, Lavenu-Bombled C, et al. Adenoviral-mediated TGF-β1 inhibition in a mouse model of myelofibrosis: inhibit bone marrow fibrosis development. Exp Hematol. 2007;35(1):64–74.
81. Rameshwar P, Narayanan R, Qian J, Denny TN, Colon C, Gascon P. NF-kappa B as a central mediator in the induction of TGF-beta 1 in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis. J Immunol. 2000;165(4):2271–2277.
82. Campanelli R, Rosti V, Villani L, et al. Evaluation of the bioactive and total transforming growth factor β1 levels in primary myelofibrosis. Cytokine. 2011;53(1):100–106.
83. Sozer S, Wang X, Zhang W, et al. Circulating angiogenic monocyte progenitor cells are reduced in JAK2V617F high allele burden myeloproliferative disorders. Blood Cells Mol Dis. 2008;41(3):284–291.
84. Verstovsek S, Kantarjian HM, Estrov Z, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012;120(6):1201–1209.
85. Wagner-Ballon O, Pisani DF, Gasztiné T, et al. Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice. Blood. 2007;110(3):345–353.
86. Thepot S, Itzykson R, Seegers V, et al; for Groupe Francophone des Myelodysplasies (GFM). Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood. 2010;116(19):3735–3742.
